- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06676527
Vorolanib in de tweedelijnsbehandeling van patiënten met inoperabel of gemetastaseerd niercelcarcinoom
Een observationeel onderzoek naar de werkzaamheid en veiligheid van Vorolanib bij de tweedelijnsbehandeling van patiënten met inoperabel of gemetastaseerd niercelcarcinoom
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted. Vorolanib is a new generation of multi-target kinase inhibitors with a new chemical structure, which can inhibit tumor angiogenesis and growth, and is used in the treatment of various cancers. This multicenter, single-arm, open-labelled observational study is designed to include patients who meet the requirements for using vorolanib as a second-line treatment for renal cell carcinoma. For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Le Qu, M. D.
- Telefoonnummer: +86 15720625951
- E-mail: septsoul@hotmail.com
Studie Locaties
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 401520
- Werving
- Jinling Hospital
-
Contact:
- Le Qu, M. D.
- Telefoonnummer: +86 15123894157
- E-mail: septsoul@hotmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Subjects clinically diagnosed with advanced unresectable or metastatic renal cell carcinoma. After receiving at least one systemic therapy (including TKIs or TKIs combined with ICIs, including but not limited to axitinib, sunitinib, sorafenib, pembrolizumab, etc.), subjects reach PD as assessed by RECIST v1.1 and switch to second-line treatment options including vorolanib.
Beschrijving
Inclusion Criteria:
- Subjects have fully understood and voluntarily signed the informed consent form (ICF);
- 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;
- Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;
- According to RECIST (version 1.1), there are targets that are considered to be observable;
- The main organs function well.
Exclusion Criteria:
- A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);
- Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;
- Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;
- A history of severe drug allergy, including but not limited to antibody drugs;
- Patients with contraindications for immunotherapy restart;
- A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;
- Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion/exclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;
- Have central nervous system metastases and/or cancerous meningitis;
- Known history of clinically significant liver disease, including those infected with viral hepatitis activity;
- Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);
- Patients with any severe and/or uncontrolled disease;
- Renal failure requires hemodialysis or peritoneal dialysis;
- Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;
- History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;
- Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;
- Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: OTHER
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Experimental cohort.
Subjects who progressed after first-line treatment and switched to second-line treatment regimens including vorolanib. The first-line treatment which patients received can be other tyrosine kinase inhibitors (TKIs) or TKIs combined with immunotherapy drugs. Provided vorolanib is contained in the second-line regimen, the patient then can be considered for inclusion in the study. |
For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Progressievrije overleving (PFS)
Tijdsspanne: Vanaf de inschrijving tot het einde van de behandeling na 12 weken.
|
Vanaf de inschrijving tot het einde van de behandeling na 12 weken.
|
|
Behandelingsgerelateerde bijwerkingen (TRAE's)
Tijdsspanne: Vanaf inschrijving tot maximaal 90 dagen na behandeling bij 12 weken of gerapporteerd.
|
Vanaf inschrijving tot maximaal 90 dagen na behandeling bij 12 weken of gerapporteerd.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Totale overleving (OS)
Tijdsspanne: Vanaf de inschrijving tot het einde van de behandeling na 12 weken.
|
Vanaf de inschrijving tot het einde van de behandeling na 12 weken.
|
|
Objectief responspercentage (ORR)
Tijdsspanne: Vanaf de inschrijving tot het einde van de behandeling na 12 weken.
|
Vanaf de inschrijving tot het einde van de behandeling na 12 weken.
|
|
Ziektecontrolepercentage (DCR)
Tijdsspanne: Vanaf de inschrijving tot het einde van de behandeling na 12 weken.
|
Vanaf de inschrijving tot het einde van de behandeling na 12 weken.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Yuxiu Liu, M. D., Jinling Hospital, China
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Urogenitale ziekten
- Neoplasmata
- Carcinoom
- Urologische ziekten
- Carcinoom, niercel
- Urologische neoplasmata
- Nier Ziekten
- Nierneoplasmata
- Urogenitale neoplasmata
- Mannelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten
Andere studie-ID-nummers
- 2024DZKY-074-02
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .